OMERS ADMINISTRATION Corp Increases Stake in DexCom, Inc. $DXCM

OMERS ADMINISTRATION Corp raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 438.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 157,201 shares of the medical device company’s stock after buying an additional 128,005 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in DexCom were worth $10,433,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Silvant Capital Management LLC grew its position in shares of DexCom by 1.6% in the 4th quarter. Silvant Capital Management LLC now owns 53,301 shares of the medical device company’s stock worth $3,538,000 after buying an additional 856 shares during the last quarter. Twin City Private Wealth LLC bought a new stake in DexCom in the fourth quarter worth $433,000. USS Investment Management Ltd boosted its holdings in DexCom by 8.3% in the fourth quarter. USS Investment Management Ltd now owns 89,480 shares of the medical device company’s stock worth $5,939,000 after acquiring an additional 6,869 shares in the last quarter. Sargent Investment Group LLC bought a new stake in DexCom in the fourth quarter worth $386,000. Finally, Mariner LLC boosted its holdings in DexCom by 92.0% in the fourth quarter. Mariner LLC now owns 84,850 shares of the medical device company’s stock worth $5,636,000 after acquiring an additional 40,654 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

DXCM has been the subject of several recent analyst reports. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Canaccord Genuity Group set a $82.00 price target on DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Mizuho set a $85.00 price target on DexCom and gave the stock an “outperform” rating in a research note on Tuesday, June 9th. Truist Financial restated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. Finally, Stifel Nicolaus set a $90.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, June 5th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $84.83.

Insider Buying and Selling

In other news, EVP Jon Coleman sold 4,911 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total value of $364,052.43. Following the sale, the executive vice president directly owned 95,450 shares in the company, valued at approximately $7,075,708.50. This represents a 4.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total value of $1,926,648.00. Following the completion of the sale, the insider owned 382,482 shares in the company, valued at approximately $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 40,994 shares of company stock valued at $2,919,022. 0.28% of the stock is currently owned by company insiders.

DexCom Stock Performance

NASDAQ DXCM opened at $74.22 on Tuesday. The firm has a market cap of $28.64 billion, a price-to-earnings ratio of 31.72, a price-to-earnings-growth ratio of 1.18 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The business has a 50-day moving average price of $66.37 and a 200-day moving average price of $67.68. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the company earned $0.32 earnings per share. The firm’s revenue was up 15.0% on a year-over-year basis. As a group, equities research analysts predict that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.